Skip to main content
OpenTrials
Completed

NCT Number: NCT00973427

DNA Chip Based Prognosis of Lung Cancer

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Aarhus University Hospital, Aarhus, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A histological diagnosis of primary NSCLC stage Ia
  • Surgical removal of the tumor
  • Age between 18 and 75 years
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

  • A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery.
  • Adjuvant treatment with chemotherapy.
  • Prior history of cancer in the past 5 years or breast cancer at any time.
  • Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.

Treatment and study plan

Primary outcomes

  1. Disease-related survival

    Time frame: 5 years

Secondary outcomes

  1. Time to progression

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

Medical Prognosis Institute A/S

Industry

Registry information

Important dates

Study start
2008
Primary completion
2014
Study completion
2014
First posted
Sep 9, 2009
Registry last updated
Sep 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.